Make an Inquiry
Accelerating Alopecia Drug Development

Alopecia presents a significant therapeutic challenge, impacting millions worldwide and lacking effective, targeted treatment options. Protheragen is a specialized partner in preclinical drug development, dedicated to advancing novel therapeutics for Alopecia. Leveraging deep scientific expertise and state-of-the-art platforms, Protheragen delivers a comprehensive suite of preclinical services—from target validation and lead optimization to IND-enabling studies—tailored to accelerate the development of innovative Alopecia therapies. Protheragen’s multidisciplinary team integrates advanced in vitro and in vivo models, robust pharmacology, and translational science to generate actionable data and de-risk candidate selection. All processes are executed under stringent regulatory standards, ensuring data integrity and facilitating seamless progression to clinical phases. With a proven track record in navigating complex preclinical landscapes, Protheragen empowers biopharmaceutical partners to efficiently advance their Alopecia drug candidates. Driven by a commitment to scientific excellence and therapeutic innovation, Protheragen is dedicated to expediting the delivery of effective Alopecia solutions to patients in need.

What is AlopeciaTargets for AlopeciaDrug Discovery and Development ServicesWhy Choose Us

What is Alopecia

Alopecia refers to hair loss from the scalp or other body areas, encompassing a diverse group of disorders with varying causes and mechanisms. Etiologies include genetic predisposition, hormonal influences (notably dihydrotestosterone in androgenetic alopecia), autoimmune responses targeting hair follicles (as seen in alopecia areata), physical or chemical trauma, and underlying systemic diseases. The pathophysiology differs by type: androgenetic alopecia involves gradual follicular miniaturization due to androgen effects, while alopecia areata is driven by immune-mediated follicular attack leading to premature hair shedding. Other forms, such as telogen effluvium, result from stress-induced shifts in the hair growth cycle, and cicatricial alopecias involve permanent follicle destruction and scarring. Clinically, alopecia presents with varying patterns, from diffuse thinning to sharply demarcated patches or scarring hair loss, often accompanied by significant psychological distress. Diagnosis relies on detailed clinical evaluation, dermoscopy, and, when indicated, laboratory tests or scalp biopsy to identify the specific type and underlying cause. Treatment is tailored to the alopecia subtype and may include topical agents like minoxidil, oral medications such as finasteride, dutasteride, or Janus kinase inhibitors (e.g., ritlecitinib, baricitinib), and targeted therapies for underlying triggers. Early intervention and comprehensive management are essential to optimize outcomes and address the psychosocial impact of the disease.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-1792180-81-4-ritlecitinib-rec-inn ritlecitinib (Rec INN) 1792180-81-4 C15 H19 N5 O 285.344
img-1187594-09-7-baricitinib-rec-inn-usan baricitinib (Rec INN; USAN) 1187594-09-7 C16 H17 N7 O2 S 371.417
img-883887-18-1-unknown 883887-18-1 C17 H16 O3 268.307
img-164656-23-9-dutasteride-prop-innm-usan dutasteride (Prop INNM; USAN) 164656-23-9 C27 H30 F6 N2 O2 528.53
img-98319-26-7-finasteride-rec-inn-usan-ban finasteride (Rec INN; USAN; BAN) 98319-26-7 C23 H36 N2 O2 372.544
img-38304-91-5-minoxidil-rec-inn-usan-ban minoxidil (Rec INN; USAN; BAN) 38304-91-5 C9 H15 N5 O 209.248
img-260980-89-0-fluridiltopilutamide-prop-inn fluridil; topilutamide (Prop INN) 260980-89-0 C13 H11 F6 N3 O5 403.234
img-57-91-0-17-alpha-estradiolalfatradiol-rec-innepiestradiol 17-alpha-estradiol; alfatradiol (Rec INN); epiestradiol 57-91-0 C18 H24 O2 272.382

Learn More

Targets for Alopecia

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
androgen receptor AR
K(ATP) Channel (nonspecified subtype)
Steroid 5-alpha-Reductase (nonspecified subtype)
transforming growth factor beta 2 TGFB2
NLRP3 Inflammasome
nuclear receptor subfamily 3 group C member 2 NR3C2
Janus kinase 1 JAK1
Janus kinase 3 JAK3
potassium voltage-gated channel subfamily D member 3 KCND3
potassium voltage-gated channel subfamily A member 5 KCNA5

Alopecia encompasses a spectrum of hair loss disorders driven by distinct molecular pathways, with several key therapeutic targets identified across androgen signaling, immune modulation, and growth factor regulation. In androgenetic alopecia (AGA), the androgen receptor (AR) and steroid 5 alpha-reductase 1 (SRD5A1) are central, mediating the effects of dihydrotestosterone (DHT) on hair follicles and promoting follicular miniaturization. In alopecia areata (AA), immune dysregulation is critical, involving targets such as interleukin 17 receptor A (IL17RA), Janus kinase 1 (JAK1), and Janus kinase 3 (JAK3), which orchestrate inflammatory cytokine signaling and T-cell mediated follicular attack. Growth factor pathways, particularly those regulated by transforming growth factor beta 2 (TGFB2), transforming growth factor beta receptor 1 (TGFBR1), and the vitamin D receptor (VDR), further modulate hair follicle cycling, differentiation, and immune privilege, contributing to disease progression in both scarring and non-scarring forms of alopecia. Therapeutically, these targets have shaped current and emerging treatment strategies. 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) and AR antagonists are established in AGA management, while JAK inhibitors (such as tofacitinib and baricitinib) have demonstrated significant efficacy in AA, supporting their role as validated immune targets. Targeting the IL-17 pathway and TGF-beta signaling represents promising avenues for modulating inflammation and fibrosis, with monoclonal antibodies and small molecule inhibitors under investigation. VDR agonists and vitamin D analogs are being explored for their potential to restore follicle cycling. Collectively, these mechanistically informed targets enable biomarker-driven drug development and personalized therapeutic approaches, aiming to improve efficacy and outcomes for patients with alopecia.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Alopecia drug discovery by providing robust screening and characterization platforms targeting key pathways such as androgen receptor, JAK1, JAK3, TGFBR1, and vitamin D receptor. Utilizing advanced biochemical and cell-based assays—including chemiluminescent, luciferase, ATP, FRET, ELISA, and binding assays—we deliver highly sensitive, quantitative evaluations of compound potency, efficacy, and selectivity. Key pharmacological parameters measured include EC-50, IC-50, Ki, and MEC. Our comprehensive approach enables precise assessment of candidate therapies, supporting data-driven decisions and optimal therapeutic development for hair growth and hair loss prevention.

Androgen Receptor Janus Kinase 1
Janus Kinase 3 Transforming Growth Factor Beta Receptor 1
Vitamin D Receptor

Learn More

Why Choose Us

Choosing Protheragen as your partner in Alopecia drug development means entrusting your project to a team with deep, specialized expertise in both Alopecia research and innovative therapeutic discovery. At Protheragen, our professional teams are composed of experienced scientists and industry experts who utilize advanced technology platforms to accelerate and optimize every stage of the preclinical development process. Our proven track record in delivering reliable preclinical drug development services stands as a testament to our commitment to quality and excellence. Protheragen adheres to the highest quality standards and maintains strict compliance with all relevant regulatory guidelines, ensuring that every project meets both scientific and regulatory expectations. Above all, Protheragen is dedicated to advancing the field of Alopecia therapeutics, continually striving to translate cutting-edge research into effective new treatments. By choosing Protheragen, you are selecting a partner that values professionalism, reliability, and a genuine commitment to improving outcomes for those affected by Alopecia.

FAQs for Our Services

Q: What are the primary preclinical research challenges specific to developing new drugs for Alopecia?

A: In preclinical research for Alopecia, a key challenge is the lack of universally accepted animal models that accurately recapitulate human hair loss conditions. Additionally, the heterogeneity of Alopecia types (such as androgenetic alopecia, alopecia areata, and scarring alopecia) complicates model selection and efficacy assessment. Our company addresses these challenges by utilizing a portfolio of validated in vivo and in vitro models, including human scalp explants and genetically engineered mice, to ensure translational relevance and robust efficacy data.

Q: What are the main regulatory considerations for preclinical development of Alopecia therapies?

A: Regulatory agencies require comprehensive safety and efficacy data before approving clinical trials for new Alopecia drugs. This includes detailed pharmacokinetic and toxicology studies, as well as demonstration of a clear mechanism of action. For topical formulations, specific dermal toxicity and irritation studies are mandatory. Our team is experienced in designing preclinical programs that align with FDA and EMA guidance, ensuring all regulatory requirements are met to facilitate a smooth IND/CTA submission process.

Q: What technical aspects should be considered when conducting preclinical research for Alopecia drug candidates?

A: Technical considerations include the selection of appropriate assay endpoints, such as hair regrowth quantification, follicle cycling analysis, and molecular biomarker assessment. Reproducibility and scalability of in vitro assays, as well as the optimization of topical versus systemic administration routes, are also critical. Our company employs advanced imaging techniques, digital quantification tools, and high-throughput screening platforms to deliver precise and reliable preclinical data.

Q: What are the typical timeline and cost considerations for preclinical development of Alopecia therapies?

A: Preclinical development timelines for Alopecia drug candidates typically range from 12 to 24 months, depending on the complexity of the compound and the required studies. Costs can vary significantly, from $1 million to $5 million, based on the extent of efficacy, pharmacokinetic, and safety studies required. We offer modular service packages and transparent budgeting to help our clients manage timelines and costs effectively, ensuring timely progression to the clinical phase.

Q: What are the key success factors in preclinical development of new drugs for Alopecia?

A: Success in preclinical Alopecia drug development hinges on robust model selection, clear demonstration of efficacy, and early identification of safety liabilities. Integration of mechanistic studies and predictive biomarkers enhances the likelihood of clinical translation. Our company’s multidisciplinary expertise, state-of-the-art facilities, and commitment to scientific rigor ensure that our clients’ drug candidates are positioned for successful clinical entry and future regulatory approval.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.